Thalidomide-O-amido-PEG3-C2-NH2 (CereblonLigand-LinkerConjugates 3) is an E3 ligase ligand-linker conjugate which is designed using Thalidomide-based cereblonligand and a 3-unit PEG linker. This compound is synthesized specifically for utilization in PROTAC technology.
Pomalidomide-PEG3-C2-NH2 TFA is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblonligand and 3-unit PEG linker used in PROTAC technology.
Thalidomide-O-amido-C3-COOH is a synthesized conjugate of an E3 ligase ligand-linker compound that combines a cereblonligand derived from Thalidomide with a linker commonly employed in PROTAC technology.
Pomalidomide-amido-PEG3-C2-NH2, known as CereblonLigand-LinkerConjugates 22, is a synthesized E3 ligase ligand-linker conjugate designed for use in PROTAC technology. It consists of the Pomalidomide-based cereblonligand and a 3-unit PEG linker. [1]
Thalidomide-O-amido-C3-NH2 is a synthesized E3 ligase ligand-linker conjugate, which combines the cereblonligand derived from Thalidomide with a linker utilized in PROTAC technology.
Pomalidomide-PEG3-C2-NH2 hydrochloride, also known as CereblonLigand-Linker Conjugate 5, is a chemically synthesized E3 ligase ligand-linker conjugate. This compound incorporates a cereblonligand based on Pomalidomide and a linker commonly employed in PROTAC technology.